使用左心室压力-应变循环评估急性心肌梗塞后心力衰竭的早期预后:一项前性随机对照临床研究
Zheng Liang1, Yaoyao Yang2, Feng Wang2
1Department of Cardiology, Lujiang County People's Hospital, Lujiang, China.
Quantitative imaging in medicine and surgery
|February 28, 2024
概括
萨库比特里尔/瓦尔萨坦和达帕格利弗洛辛的联合治疗在心力衰竭患者心肌梗塞 (MI) 后的心脏功能中适度改善. 左心室压力-应变循环 (LV-PSL) 分析显示出更好的结果,可以预测这些患者的预后.
科学领域:
- 心脏病学 心脏病学
- 心血管成像 - 心血管成像
- 药理学 药理学是指药理学的学科.
背景情况:
- 左心室压力-应变循环 (LV-PSL) 是一种敏感的,非侵入性的方法来评估心肌功能.
- 心肌梗塞 (MI) 后心力衰竭与减少喷射率 (HFrEF) 需要有效的治疗策略.
- 评估新的治疗组合对于改善HFrEF患者的心脏功能至关重要.
研究的目的:
- 为了评估与sacubitril/valsartan单独治疗相比,sacubitril/valsartan加达帕格利弗洛辛在改善HFrEF患者心脏功能的疗效后MI.
- 评估LV-PSL在检测心肌功能变化和预测该患者队列的预后方面的作用.
主要方法:
- 这是一项前性,多中心的开放性研究,涉及60名心脏病发作后的HFrEF患者.
- 随机 1:1 分配到观察组 (萨库比特里尔/瓦尔萨坦 + 达帕格利弗洛辛) 或对照组 (萨库比特里尔/瓦尔萨坦单疗法).
- 在基线和出院后1,3,6个月使用LV-PSL (全球工作指数,全球建设性工作) 和LV-GLS评估心脏功能.
主要成果:
- 两组均显示LV-GLS和心肌工作指数有所改善.
- 观察组在6个月后在全球工作指数 (GWI) 和全球建设性工作 (GCW) 中表现出显著更大的改善 (分别P=0.03和P=0.04).
- 组合疗法与重大心血管不良事件 (MACE) 的发生率显著降低 (P=0.03),GCW是MACE的独立预测因子 (P<0.001).
结论:
- 与单独使用sacubitril/valsartan相比,sacubitril/valsartan加达帕格利弗洛辛在MI后的HFrEF患者中提供了适度的心脏功能改善.
- LV-PSL分析是评估心脏病发作后心力衰竭 (P-MI-HF) 患者早期预后的一个有价值的工具.
- 组合疗法可以减少MACE,强调全面的心脏功能评估的重要性.
相关概念视频
01:20Mitral Regurgitation I: Introduction
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
01:27Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:28Cardiomyopathy VII: Pre and Post Operative Nursing Management
Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...